- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Interventions
- DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
- Biological
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Buffalo, New York • Durham, North Carolina + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 15,613
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
- Interventions
- NM21-1480
- Biological
- Lead sponsor
- Numab Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 14
- States / cities
- Fort Collins, Colorado • Augusta, Georgia • New Orleans, Louisiana + 11 more
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Melanoma of the Skin, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer
- Interventions
- Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, TLR8 Agonist VTX-2337
- Drug · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Interventions
- HLX17, US-sourced Keytruda®
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more
- Conditions
- Collagen Degeneration, Wrinkle, Pigmentation, Elastic Skin, Sebum Deficiency
- Interventions
- Topical Product: Almond Oil, Topical Product: Almond oil augmented with 0.5% Vitamin E, Topical Product: 0.025% Tretinoin oil augmented with castor oil
- Other
- Lead sponsor
- Integrative Skin Science and Research
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
- Interventions
- rilonacept 160 mg, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more
- Conditions
- Infected Toenails, Onychomycosis
- Interventions
- PinPointe FootLaser
- Device
- Lead sponsor
- PathoLase, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Rochester, New York • San Antonio, Texas • Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2016
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Rochester, Minnesota + 1 more
- Conditions
- Breast Cancer
- Interventions
- Carbohydrate restricted dietary intervention, standard of care aromatase inhibitors
- Other · Drug
- Lead sponsor
- Monica Mita
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hypochondroplasia
- Interventions
- Not listed
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 30 Months to 16 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Psoriasis, Cardiovascular Disease
- Interventions
- Tildrakizumab
- Drug
- Lead sponsor
- Marcelo F. Di Carli, MD, FACC
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lipedema, Lipolymphedema
- Interventions
- Flexitouch Plus and Conservative Care, Conservative Care
- Device · Other
- Lead sponsor
- Thomas Wright, MD
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- O'Fallon, Missouri
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- doxorubicin hydrochloride, suramin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- GATA2 Deficiency
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hereditary Angioedema
- Interventions
- Lanadelumab
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 11
- States / cities
- Santa Monica, California • Walnut Creek, California • Centennial, Colorado + 8 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- XmAb5871, Placebo to match XmAb5871
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 23
- States / cities
- La Jolla, California • Loma Linda, California • San Leandro, California + 17 more
- Conditions
- Breast Cancer
- Interventions
- gene expression analysis, mutation analysis, proteomic profiling, reverse transcriptase-polymerase chain reaction, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, medical chart review, quality-of-life assessment
- Genetic · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 20 Years and older · Female only
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Duarte, California • Pasadena, California
- Conditions
- Coccidioidomycosis, Blastomycosis, Histoplasmosis, Dimorphic Fungal Infection, Endemic Mycoses
- Interventions
- Oteseconazole
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Davis, California + 1 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Not listed
- Lead sponsor
- Power Life Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Atopic Dermatitis
- Interventions
- AK002, Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 33 more
- Conditions
- Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- Interventions
- Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 55
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more
- Conditions
- Rosacea
- Interventions
- Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream
- Drug · Other
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more
- Conditions
- Diabetes, Type 1, Diabetes, Type 2, Foot Ulcer, Diabetic
- Interventions
- Bacitracin, AmeriGel®, Vitamin C
- Drug · Dietary Supplement
- Lead sponsor
- Susan Hassenbein
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania